{"ATC Code":["C02AC01","N - Nervous system","N02 - Analgesics","N02C - Antimigraine preparations","N02CX - Other antimigraine preparations","N02CX02 - Clonidine","C - Cardiovascular system","C02 - Antihypertensives","C02A - Antiadrenergic agents, centrally acting","C02AC - Imidazoline receptor agonists","C02AC01 - Clonidine","S - Sensory organs","S01 - Ophthalmologicals","S01E - Antiglaucoma preparations and miotics","S01EA - Sympathomimetics in glaucoma therapy","S01EA04 - Clonidine","QN - Nervous system","QN02 - Analgesics","QN02C - Antimigraine preparations","QN02CX - Other antimigraine preparations","QN02CX02 - Clonidine","QS - Sensory organs","QS01 - Ophthalmologicals","QS01E - Antiglaucoma preparations and miotics","QS01EA - Sympathomimetics in glaucoma therapy","QS01EA04 - Clonidine","QC - Cardiovascular system","QC02 - Antihypertensives","QC02A - Antiadrenergic agents, centrally acting","QC02AC - Imidazoline receptor agonists","QC02AC01 - Clonidine"],"Absorption, Distribution and Excretion":"Clonidine reaches maximum concentration in 60-90 minutes after oral administration. Race and fasting status do not influence pharmacokinetics of clonidine.  A 100µg oral clonidine tablet reaches a Cmax of 400.72pg/mL with an AUC of 5606.78h\\*pg/mL and a bioavailability of 55-87%.","Adverse Effects":"Like any other medication, clonidine has the potential for short-term and long-term side effects. Some of the common side effects based on FDA reports include:","Aliases":["Clonidine","Clonidin","N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine","Chlornidinum","Catapres-TTS","ST-155-BS","Catapresan","Catapressan","Clonidina","ST 155BS","Catapres-tts-1","Catapres-tts-2","Catapres-tts-3","Clonidinum","Catarpres-TTS","Nexiclon XR","2-((2,6-Dichlorophenyl)imino)imidazolidine","2,6-Dichloro-N-2-imidazolidinylidenebenzenamine","734571A","Chlofazoline","Clonidine extended release","Benzenamine, 2,6-dichloro-N-2-imidazolidinylidene-","M 5041T","CHEBI:3757","Dtxsid6022846","2-[(2,6-Dichlorophenyl)imino]imidazoline","Dtxcid402846","2-[(2,6-Dichlorophenyl)imino]imidazolidine","Chebi:46632","Clofenil","Clopheline","Klofenil","2-((2,6-Dichlorophenyl)imino)imidazoline","Hydrochloride, Clonidine","Dihydrochloride, Clonidine","Monohydrobromide, Clonidine","Monohydrochloride, Clonidine","Clonidine Transdermal System","Chebi:46631","C02AC01","N02CX02","S01EA04","ST155","M5041T","Clonidine Transdermal System USP, 0.1 mg/day","Clonidine Transdermal System USP, 0.2 mg/day","Clonidine Transdermal System USP, 0.3 mg/day","224-119-4","ST 155","Catapres","Adesipress","Catarpres","Catarpresan","2-(2,6-Dichloroanilino)-2-imidazoline","Clonidinhydrochlorid","SKF 34427","M-5041T","CLORPRES","2-(2,6-Dichlorophenylamino)-2-imidazoline","2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)","CCRIS 7787","HSDB 3040","1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-","[3H]clonidine","Clonidine(200mg)","2,6-dichloro-N-imidazolidin-2-ylideneaniline","ST-155BS","2-Imidazoline, 2-(2,6-dichloroanilino)-","Ncgc00015268-05","Catapres- TTS","Dichloranilino imidazolin","Cas-4205-90-7","Einecs 224-119-4","Cas-4205-91-8","Unii-mn3l5rmn02","Kapvay\u0026reg","Sr-01000759380","3h-clonidine","Mfcd00055059","Clonidine(200 mg)","Spectrum_001341","Tocris-0690","2-(2,6-Dichlorophenylimino)imidazolidine","starbld0009556","N-(2,6-dichlorophenyl)imidazolidin-2-imine","Prestwick0_000248","Prestwick1_000248","Prestwick2_000248","Prestwick3_000248","Spectrum2_001187","Spectrum3_000358","Spectrum4_000956","Spectrum5_000759","Lopac-C-7897","2-[(2,6-dichlorophenyl)imino]-2-imidazoline","CHEMBL134","D00281","Schembl5982","Schembl5983","2,6-dichloro-N-2-imidazolidinylidenebenzenamide","Lopac0_000268","BSPBio_000036","BSPBio_001588","BSPBio_002055","GTPL516","KBioGR_000308","KBioGR_001572","KBioSS_000308","KBioSS_001821","Mls006011925","Bidd:gt0547","DivK1c_000774","SPBio_001233","SPBio_002255","BPBio1_000040","orb1300116","Schembl2457114","Schembl2457117","BDBM14062","GTPL13162","KBio1_000774","KBio2_000308","KBio2_001821","KBio2_002876","KBio2_004389","KBio2_005444","KBio2_006957","KBio3_000615","KBio3_000616","KBio3_001275","Ninds_000774","Bio1_000470","Bio1_000959","Bio1_001448","Bio2_000308","Bio2_000788","GLXC-07073","HMS1361P10","HMS1791P10","HMS1989P10","HMS2089G11","HMS3402P10","CLONIDINE, Clonidine hydrochloride","Tox21_110118","BBL025137","Bdbm50016897","Bdbm50020341","Bdbm50225285","EBC-26254","HY-12721R","STL355995","Akos001595470","Akos015960367","Tox21_110118_1","CCG-204363","DB00575","Sdccgsbi-0050256.p005","Idi1_000774","Idi1_034058","Mrf-0000018","Ncgc00015268-01","Ncgc00015268-02","Ncgc00015268-03","Ncgc00015268-04","Ncgc00015268-06","Ncgc00015268-07","Ncgc00015268-08","Ncgc00015268-12","Ncgc00024734-01","Ncgc00024734-02","Ncgc00024734-03","Ncgc00024734-04","Ncgc00024734-05","Ncgc00179680-01","Ncgc00179680-02","Ncgc00179680-03","Ncgc00179680-05","HY-12721","Smr001550184","SY267931","2-(2,6-dichlorophenylimino)-imidazolidine","Sbi-0050256.p004","2-(2,6-dichlorophenyl-imino)-imidazolidine","AB00514634","CS-0012297","NS00010455","2-(2',6'-dichlorophenylamino)-2-imidazoline","2-[(2,6-dichlorophenyl)imino]-imidazolidine","F74813","Ab00053441_03","Ab00514634-07","Ab00514634-08","Ab00514634_09","En300-8686697","(2,6-Dichlorophenyl)imidazolidin-2-ylidene amine","F869752","L000193","(2,6-dichloro-phenyl)-imidazolidin-2-ylidene-amine","Sr-01000759380-4","2-Imidazoline, 2-(2,6-dichlorophenylamino)-","Brd-k98530306-001-02-1","Brd-k98530306-003-05-0","Brd-k98530306-003-07-6","Brd-k98530306-003-16-7","Brd-k98530306-003-17-5","Brd-k98530306-003-18-3","N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine #"],"Biological Half-Life":"The elimination half life after epidural administration is 30 minutes but otherwise can range from 6-23h.","CAS":"4205-90-7","Chemical Classes":"Pharmaceutical","ChemicalClasses":["aniline"],"Chirality":"achiral","Color/Form":"Crystals","DBI-IGS":["Clonidine"],"Decomposition":"When heated to decomposition it emits toxic fumes of nitroxides and /hydrogen chloride/. /Clonidine hydrochloride/","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Entries":0,"Lower":0.1,"Percentage":0,"Unit":"mg","Upper":0.1},"Extreme":{"Entries":0,"Lower":0.2,"Percentage":0,"Unit":"mg","Upper":0.2},"Heavy":{"Entries":2,"Lower":0.2,"Percentage":28.6,"Unit":"mg","Upper":0.2},"Light":{"Entries":5,"Lower":0.1,"Percentage":71.4,"Unit":"mg","Upper":0.1},"Strong":{"Entries":0,"Lower":0.1,"Percentage":0,"Unit":"mg","Upper":0.2}}}],"Drug Classes":["Breast Feeding","Lactation","Milk, Human","Antihypertensive Agents","Adrenergic alpha-2 Receptor Agonists"],"Drug Indication":"Clonidine tablets, oral solution and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications. A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient. An extended-release tablet of clonidine is indicated for the treatment of ADHD, either alone or in combination with other medications.  Clonidine is also used for the diagnosis of pheochromocytoma, treatment of nicotine dependance, and opiate withdrawal.  Additionally, clonidine is also indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy or as an adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.","Drug Warnings":"Abrupt withdrawal of clonidine therapy may result in a rapid increase of systolic and diastolic blood pressures with associated symptoms such as nervousness, agitation, confusion, restlessness, anxiety, insomnia, headache, sweating, palpitation, increased heart rate, tremor, hiccups, stomach pains, nausea, muscle pains, and increased salivation. The exact mechanism(s) of the withdrawal syndrome following discontinuance of alpha-adrenergic agonists has not been determined but may involve increased concentrations of circulating catecholamines, increased sensitivity of adrenergic receptors, enhanced renin-angiotensin system activity, decreased vagal function, failure of autoregulation of cerebral blood flow, and/or failure of central alpha2-adrenergic receptor mechanisms that regulate sympathetic outflow from the CNS and modulate baroreflex function.","DurationOfAction":"Blood pressure:\n≤ 8 hours ADHD: 4 – 8 hours\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e","EliminationHalfLife":"IR: 12 – 16 hours; 41 hours in kidney failure, 48 hours for repeated dosing","Esters":[],"European Community (EC) Number":"224-119-4","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":28,"Value":{"StringWithMarkup":[{"String":"MN3L5RMN02"}]}},{"Name":"Active Moiety","ReferenceNumber":28,"Value":{"StringWithMarkup":[{"String":"CLONIDINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":28,"Value":{"StringWithMarkup":[{"String":"Mechanisms of Action [MoA] - Adrenergic alpha2-Agonists"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":28,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - Central alpha-2 Adrenergic Agonist"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":28,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-2803","Length":9,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Clonidine"},{"Extra":"CID-2803","Length":9,"Start":78,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/clonidine"}],"String":"Clonidine is a Central alpha-2 Adrenergic Agonist. The mechanism of action of clonidine is as an Adrenergic alpha2-Agonist."}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":93,"Value":{"StringWithMarkup":[{"String":"CLONIDINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":93,"Value":{"StringWithMarkup":[{"String":"Central alpha-2 Adrenergic Agonist [EPC]; Adrenergic alpha2-Agonists [MoA]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":94,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-2803","Length":9,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/CLONIDINE"}],"String":"CLONIDINE TRANSDERMAL SYSTEM"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":94,"Value":{"StringWithMarkup":[{"String":"Central alpha-2 Adrenergic Agonist [EPC]; Adrenergic alpha2-Agonists [MoA]"}]}}],"Formating":[],"HMDB ID":"HMDB0014714","HeavyAtomCount":14,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic alpha-2 Receptor Agonists","IUPACName":"N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine","InChI":"InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)","InChIKey":"GJSURZIOUXUGAL-UHFFFAOYSA-N","Interactions":"Potential additive effects (eg, hypotension, bradycardia). If carvedilol is used concomitantly with clonidine, caution should be exercised, particularly when discontinuing therapy; carvedilol generally should be discontinued first, and clonidine continued for several days thereafter with gradual downward dosage titration.","KEGG Entries":[{"Id":"D00281","Interactions":[],"Synonyms":["Clonidine","Catarpres-TTS"]},{"Id":"D00604","Interactions":[],"Synonyms":["Clonidine hydrochloride","Nexiclon","Kapvay","Duraclon","Catapres"]},{"Id":"D10591","Interactions":[],"Synonyms":["Clonidine and chlorthalidone","Clorpres"]},{"Id":"D00281","Interactions":[],"Synonyms":["Clonidine","Catarpres-TTS"]},{"Id":"D00604","Interactions":[],"Synonyms":["Clonidine hydrochloride","Nexiclon","Kapvay","Duraclon","Catapres"]},{"Id":"D10591","Interactions":[],"Synonyms":["Clonidine and chlorthalidone","Clorpres"]},{"Id":"D00281","Interactions":[],"Synonyms":["Clonidine","Catarpres-TTS"]},{"Id":"D00604","Interactions":[],"Synonyms":["Clonidine hydrochloride","Nexiclon","Kapvay","Duraclon","Catapres"]},{"Id":"D10591","Interactions":[],"Synonyms":["Clonidine and chlorthalidone","Clorpres"]}],"MeSH Headers":[{"Id":"M0004605","Link":"https://id.nlm.nih.gov/mesh/M0004605.html","Name":"Clonidine","Ref":138},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":140},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":169},{"Id":"M0001067","Link":"https://id.nlm.nih.gov/mesh/M0001067.html","Name":"Analgesics","Ref":170},{"Id":"M0001456","Link":"https://id.nlm.nih.gov/mesh/M0001456.html","Name":"Antihypertensive Agents","Ref":171},{"Id":"M0020945","Link":"https://id.nlm.nih.gov/mesh/M0020945.html","Name":"Sympatholytics","Ref":172},{"Id":"M0543921","Link":"https://id.nlm.nih.gov/mesh/M0543921.html","Name":"Adrenergic alpha-2 Receptor Agonists","Ref":173}],"MeSH Pharmacological Classification":[{"Id":"M0001067","Link":"https://id.nlm.nih.gov/mesh/M0001067.html","Name":"Analgesic","Ref":170},{"Id":"M0001456","Link":"https://id.nlm.nih.gov/mesh/M0001456.html","Name":"Antihypertensive Agent","Ref":171},{"Id":"M0020945","Link":"https://id.nlm.nih.gov/mesh/M0020945.html","Name":"Sympatholytic","Ref":172},{"Id":"M0543921","Link":"https://id.nlm.nih.gov/mesh/M0543921.html","Name":"Adrenergic alpha-2 Receptor Agonist","Ref":173}],"Mechanism of Action":"Clonidine is primarily an alpha-2 adrenoceptor agonist which causes central hypotensive and anti-arrhythmogenic effects. The alpha-2 adrenoceptor is coupled to the G-proteins G\u003csub\u003eo\u003c/sub\u003e and G\u003csub\u003ei\u003c/sub\u003e. G\u003csub\u003ei\u003c/sub\u003e inhibits adenylyl cyclase and activates opening of a potassium channel that causes hyperpolarization. Clonidine binding to the alpha-2 adrenoceptor causes structural changes in the alpha subunit of the G-protein, reducing its affinity for GDP. Magnesium catalyzes the replacement of GDP with GTP. The alpha subunit dissociates from the other subunits and associates with an effector.  The stimulation of alpha-2 adrenoceptors in the locus coeruleus may be responsible for the hypnotic effects of clonidine as this region of the brain helps regulate wakefulness. Clonidine can also decrease transmission of pain signals at the spine. Finally clonidine can affect regulators of blood pressure in the ventromedial and rostral-ventrolateral areas of the medulla.","Melting Point":"130 °C","Metabolism/Metabolites":"The metabolism of clonidine is poorly understood. The main reaction in clonidine metabolism is the 4-hydroxylation of clonidine by CYP2D6, CYP1A2, CYP3A4, CYP1A1, and CYP3A5.  Clonidine is \u003c50% metabolized in the liver to inactive metabolites.","MolecularFormula":"C\u003csub\u003e9\u003c/sub\u003eH\u003csub\u003e9\u003c/sub\u003eCl\u003csub\u003e2\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"230.09 g/mol","Non-Human Toxicity Values":"LD50 Rat oral 126 mg/kg /Clonidine hydrochloride/","Pharmacodynamics":"Clonidine functions through agonism of alpha-2 adrenoceptors which have effects such as lowering blood pressure, sedation, and hyperpolarization of nerves. It has a long duration of action as it is given twice daily and the therapeutic window is between 0.1mg and 2.4mg daily.","Physical Description":"Solid","PubChemId":2803,"Record Description":["LiverTox|Cardiac|Antihypertensive|Miscellaneous"],"Records":{"UNII":{"Impurities":["clonidine dimer","n-acetylclonidine"]}},"RefChem":"5698","RefCount":5,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Clonidine","Name":"Clonidine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q412221","Name":"Clonidine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB00575","Name":"Clonidine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2803","Name":"Clonidine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=4205-90-7","Name":"Clonidine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014714","Name":"Clonidine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00281","Name":"Clonidine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/MN3L5RMN02","Name":"Clonidine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6022846","Name":"Clonidine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2803, Clonidine. Accessed April 16, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2803\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2803\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Clonidine. UNII: MN3L5RMN02. Global Substance Registration System. Accessed April 16, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/MN3L5RMN02\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/MN3L5RMN02\u003c/a\u003e","CATAPRES clonidine hydrochloride 150 microgram/1mL injection ampoule (17919). August 12, 2022. Accessed April 16, 2026. \u003ca href=https://www.tga.gov.au/resources/artg/17919\u003ehttps://www.tga.gov.au/resources/artg/17919\u003c/a\u003e","Efron D, Coscini N. Pharmacological management of attention deficit hyperactivity disorder in children and adolescents. Australian Prescriber. October 14, 2025; 48(5)"],"SMILES":"C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl","SaltData":[{"AcidCount":1,"Amine":"Clonidine","AmineCount":1,"Formula":"Cl","Name":"hydrochloride","RName":"hydrochloride","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 101.858 52.141\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h102v53H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m70.333 44.428 7.562-13.146M77.895 31.282l-7.346-8.117\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m64.451 21.427-10.615 4.77M65.451 23.652 56.44 27.7\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m64.451 21.427-5.308 2.385M65.451 23.652l-4.506 2.024\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m53.836 26.197 1.153 11.34M70.333 44.428l-11.64-2.373M53.836 26.197l-10.045-5.8M37.484 20.397l-10.044 5.8\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.444 41.445-.004-15.248M25.006 40.038l-.004-12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.444 41.445-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.043 41.437 13.203 7.628M3.481 40.029l10.766 6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.043 41.437-.005-15.249\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.236 18.568-13.198 7.62M14.236 21.384 3.477 27.596\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.44 26.197-13.204-7.629M14.236 18.568l.002-11.321M27.444 41.445l10.254 5.918\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M69.61 22.431h-.72l-2.62-4.066h-.029l.029.596q.024.357.024.732v2.738h-.565v-4.899h.714l2.607 4.054h.03l-.018-.327q-.012-.221-.023-.477-.006-.262-.006-.482v-2.768h.577z\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M57.321 43.829H56.6l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566V38.93h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482V38.93h.578zM52.878 43.829h-.62v-2.286h-2.512v2.286h-.613V38.93h.613v2.071h2.512V38.93h.62z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M42.578 21.026h-.72l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566v-4.899h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482v-2.768h.577zM42.442 15.565h-.62v-2.286H39.31v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.62z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#1ff01f\" stroke=\"none\" d=\"M14.733 1.352q-.786 0-1.238.53-.453.523-.453 1.446 0 .911.417 1.447.423.53 1.268.53.321 0 .607-.054.292-.059.566-.143v.536q-.274.101-.566.149-.291.053-.696.053-.744 0-1.25-.309-.501-.31-.751-.875-.25-.572-.25-1.34 0-.744.268-1.309.274-.566.804-.882.53-.321 1.28-.321.78 0 1.351.286l-.244.524q-.226-.102-.506-.185-.274-.083-.607-.083m2.757 4.423h-.602V.56h.602zM41.138 47.087q-.786 0-1.238.529-.453.524-.453 1.447 0 .911.417 1.447.423.529 1.268.529.321 0 .607-.053.292-.06.566-.143v.536q-.274.101-.566.149-.291.053-.696.053-.744 0-1.25-.309-.501-.31-.751-.875-.25-.572-.25-1.34 0-.744.268-1.31.274-.565.804-.881.53-.321 1.28-.321.78 0 1.351.286l-.244.523q-.226-.101-.506-.184-.274-.083-.607-.083m2.757 4.423h-.602v-5.215h.602z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m70.549 23.165 3.673 4.059M54.989 37.537l-.577-5.67M54.989 37.537l-.577-5.67M58.693 42.055l5.82 1.187M58.693 42.055l5.82 1.187M43.791 20.397l5.022 2.9M43.791 20.397l5.022 2.9M37.484 20.397l-5.022 2.9M37.484 20.397l-5.022 2.9\" class=\"hi\"/\u003e\u003cpath stroke=\"#1ff01f\" d=\"m14.238 7.247-.001 5.661M37.698 47.363l-5.127-2.959\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg fill=\"#1ff01f\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M98.541 24.219q-.786 0-1.238.53-.453.524-.453 1.447 0 .91.417 1.446.423.53 1.268.53.322 0 .607-.054.292-.059.566-.142v.535q-.274.102-.566.149-.291.054-.696.054-.744 0-1.25-.31-.5-.309-.75-.875-.25-.571-.25-1.339 0-.744.268-1.31.273-.566.803-.881.53-.322 1.28-.322.78 0 1.351.286l-.244.524q-.226-.101-.506-.184-.273-.084-.607-.084m2.757 4.423h-.601v-5.215h.601zM95.634 28.642h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Clonidine hydrochloride","UNII":"W76I6XXF06"}],"Salts":["hydrochloride"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"}],"Solubility":"Insoluble in water","Stability/Shelf Life":"STABLE IN LIGHT, AIR, \u0026 HEAT /HCL/","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 78.949 52.141\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h79v53H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m70.333 44.428 7.562-13.146M77.895 31.282l-7.346-8.117\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m64.451 21.427-10.615 4.77M65.451 23.652 56.44 27.7\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m64.451 21.427-5.308 2.385M65.451 23.652l-4.506 2.024\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m53.836 26.197 1.153 11.34M70.333 44.428l-11.64-2.373M53.836 26.197l-10.045-5.8M37.484 20.397l-10.044 5.8\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.444 41.445-.004-15.248M25.006 40.038l-.004-12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.444 41.445-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.043 41.437 13.203 7.628M3.481 40.029l10.766 6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.043 41.437-.005-15.249\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.236 18.568-13.198 7.62M14.236 21.384 3.477 27.596\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.44 26.197-13.204-7.629M14.236 18.568l.002-11.321M27.444 41.445l10.254 5.918\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M69.61 22.431h-.72l-2.62-4.066h-.029l.029.596q.024.357.024.732v2.738h-.565v-4.899h.714l2.607 4.054h.03l-.018-.327q-.012-.221-.023-.477-.006-.262-.006-.482v-2.768h.577z\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M57.321 43.829H56.6l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566V38.93h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482V38.93h.578zM52.878 43.829h-.62v-2.286h-2.512v2.286h-.613V38.93h.613v2.071h2.512V38.93h.62z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M42.578 21.026h-.72l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566v-4.899h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482v-2.768h.577zM42.442 15.565h-.62v-2.286H39.31v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.62z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#1ff01f\" stroke=\"none\" d=\"M14.733 1.352q-.786 0-1.238.53-.453.523-.453 1.446 0 .911.417 1.447.423.53 1.268.53.321 0 .607-.054.292-.059.566-.143v.536q-.274.101-.566.149-.291.053-.696.053-.744 0-1.25-.309-.501-.31-.751-.875-.25-.572-.25-1.34 0-.744.268-1.309.274-.566.804-.882.53-.321 1.28-.321.78 0 1.351.286l-.244.524q-.226-.102-.506-.185-.274-.083-.607-.083m2.757 4.423h-.602V.56h.602zM41.138 47.087q-.786 0-1.238.529-.453.524-.453 1.447 0 .911.417 1.447.423.529 1.268.529.321 0 .607-.053.292-.06.566-.143v.536q-.274.101-.566.149-.291.053-.696.053-.744 0-1.25-.309-.501-.31-.751-.875-.25-.572-.25-1.34 0-.744.268-1.31.274-.565.804-.881.53-.321 1.28-.321.78 0 1.351.286l-.244.523q-.226-.101-.506-.184-.274-.083-.607-.083m2.757 4.423h-.602v-5.215h.602z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m70.549 23.165 3.673 4.059M54.989 37.537l-.577-5.67M54.989 37.537l-.577-5.67M58.693 42.055l5.82 1.187M58.693 42.055l5.82 1.187M43.791 20.397l5.022 2.9M43.791 20.397l5.022 2.9M37.484 20.397l-5.022 2.9M37.484 20.397l-5.022 2.9\" class=\"hi\"/\u003e\u003cpath stroke=\"#1ff01f\" d=\"m14.238 7.247-.001 5.661M37.698 47.363l-5.127-2.959\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Adrenergic alpha-Agonists; Antihypertensive Agents; Sympatholytics; Analgesics","Title":"Clonidine","Toxicity Data":"LD50: 150 mg/kg (oral, rat)\nLD50: 30 mg/kg (oral, dog) ","Treatment":"There is no specific antidote for clonidine overdosage. Clonidine overdosage may result in the rapid development of CNS depression; therefore, induction of vomiting with ipecac syrup is not recommended. Gastric lavage may be indicated following recent and/or large ingestions. Administration of activated charcoal and/or a cathartic may be beneficial. Supportive care may include atropine sulfate for bradycardia, intravenous fluids and/or vasopressor agents for hypotension and vasodilators for hypertension. Naloxone may be a useful adjunct for the management of clonidine-induced respiratory depression, hypotension and/or coma; blood pressure should be monitored since the administration of naloxone has occasionally resulted in paradoxical hypertension. Tolazoline administration has yielded inconsistent results and is not recommended as first-line therapy. (L1712)","UNII":"MN3L5RMN02","Wikidata":"Q412221","Wikipedia":"Clonidine","XLogP":1.6}